Pharmacokinetic evaluation of fosaprepitant dimeglumine | 合法藥品大搜索

由 KP Garnock-Jones 著作 · 2016 · 被引用 4 次 — Intravenous fosaprepitant dimeglumine (Emend(®) for injection, IVEmend(®); henceforth referred to as fosaprepitant) is a prodrug of and is rapidly converted ... Read More

由 N Candelario 著作 · 2016 · 被引用 6 次 — Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used ... Read More

由 F Colon-Gonzalez 著作 · 2010 · 被引用 25 次 — Fosaprepitant is an intravenous prodrug of aprepitant that offers a new alternative to patients with CINV. Currently, fosaprepitant can substitute oral ... Read More

A drug used together with other drugs to prevent and control nausea and vomiting caused by cancer treatment. It is given in a vein. It is a type of antiemetic ... Read More

Fosaprepitant dimeglumine is an organoammonium salt obtained by reaction of fosaprepitant with two equivalents of 1-deoxy-1-(methylamino)-D-glucitol. A ... Read More

Fosaprepitant dimeglumine is a white to off-white amorphous powder with a molecular weight of 1004.83. It is freely soluble in water. Read More

IVEMEND 150 mg powder for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each vial contains fosaprepitant dimeglumine equivalent to 150 mg ... Read More

由 N Candelario 著作 · 2016 · 被引用 6 次 — Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic ... Read More

Each vial contains fosaprepitant dimeglumine equivalent to 150 mg fosaprepitant, which corresponds to 130.5 mg of aprepitant. Read More

Fosaprepitant is an antiemetic medication, administered intravenously. ... Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, ... Read More